MAP2K7 and graft versus host disease: First, because even if MEK inhibitors have been mainly developed as antineoplastic agents, numerous studies support that targeting MEK limits cytokine responses in various contexts like graft-vs-host disease, cerebral ischemia, activation of T cells by superantigens or influenza A infection53–58.